Epidiolex for Sturge-Weber Syndrome

(Epi-Pre Trial)

AC
BK
Overseen ByBrenna Keam, BS
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines whether Epidiolex, a form of cannabidiol, can delay seizures in young children with Sturge-Weber syndrome, a rare condition causing skin and brain abnormalities. Seizures can worsen brain outcomes, so the trial aims to determine if starting treatment before seizures begin can make a difference. It focuses on children aged 1 to 18 months who have been diagnosed with Sturge-Weber syndrome but have not yet experienced seizures. Participants should not have severe liver disease or other uncontrolled medical issues. As a Phase 2 trial, the research measures how well the treatment works in an initial, smaller group of people.

Is there any evidence suggesting that Epidiolex is likely to be safe for humans?

Research has shown that Epidiolex, a CBD oral solution, is generally safe for patients. The FDA has already approved Epidiolex to treat seizures in conditions like Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex, indicating thorough testing for these conditions.

In past studies, patients tolerated Epidiolex well, with most side effects being mild to moderate, such as sleepiness, reduced appetite, and diarrhea. Serious side effects were rare.

For those considering joining a clinical trial for Epidiolex to treat Sturge-Weber syndrome, these findings suggest it is likely safe, based on its use in other seizure-related conditions.12345

Why do researchers think this study treatment might be promising?

Epidiolex is unique because it's derived from cannabidiol (CBD), a component of cannabis, which offers a new mechanism of action for treating Sturge-Weber Syndrome. Unlike traditional treatments that primarily focus on controlling seizures with anticonvulsants, Epidiolex targets the endocannabinoid system, potentially offering a different pathway to manage symptoms. Researchers are excited about this treatment because it may provide better seizure control with fewer side effects, thanks to its plant-based origin.

What evidence suggests that Epidiolex might be an effective treatment for Sturge-Weber syndrome?

Research has shown that Epidiolex, a type of cannabidiol (CBD), may help reduce seizures in people with Sturge-Weber syndrome (SWS). Studies have found that some patients experienced more than a 50% decrease in seizures after using CBD for several weeks. In this trial, participants will receive presymptomatic Epidiolex treatment to evaluate its potential in managing SWS symptoms and possibly delaying the onset of seizures. Besides controlling seizures, Epidiolex may also enhance quality of life, mood, and brain function. It has demonstrated benefits for neurological and cognitive improvements, even when not directly linked to seizure control.678910

Who Is on the Research Team?

RF

Ryan Felling, MD, PhD

Principal Investigator

Johns Hopkins School of Medicine

Are You a Good Fit for This Trial?

This trial is for people diagnosed with Sturge-Weber syndrome who have not yet had seizures. Participants should be presymptomatic, meaning they haven't shown seizure symptoms but are at risk due to their condition.

Inclusion Criteria

Patient's parent or legal guardian provides written informed consent prior to treatment initiation
I have never had a seizure.
I am between 1 and 18 months old.
See 2 more

Exclusion Criteria

I have not had major surgery or serious injury in the past 4 weeks and have recovered from any recent major surgery.
I am currently taking medication to prevent or control seizures.
Severe and/or uncontrolled medical conditions at randomization
See 10 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Epidiolex starting at 2.5 mg/kg/day with weekly increases over 5 weeks to a target dose of 20 mg/kg/day

6 months
Visits at baseline, week 5, week 12, and week 24

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Epidiolex

Trial Overview

The study tests whether taking Epidiolex (a cannabidiol oral solution) before any seizures start can delay or prevent seizures and improve brain health in people with Sturge-Weber syndrome.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Presymptomatic Epidiolex TreatmentExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Johns Hopkins University

Lead Sponsor

Trials
2,366
Recruited
15,160,000+

Jazz Pharmaceuticals

Industry Sponsor

Trials
252
Recruited
35,100+
Bruce C. Cozadd profile image

Bruce C. Cozadd

Jazz Pharmaceuticals

Chief Executive Officer since 2009

BA in Economics from Yale University, MBA from Stanford University

Dr. Austin profile image

Dr. Austin

Jazz Pharmaceuticals

Chief Medical Officer since 2023

MD from the Royal College of Surgeons in Ireland

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Collaborator

Trials
93
Recruited
25,200+

Citations

Cannabidiol Treatment for Refractory Seizures in Sturge- ...

Two subjects at week 14 and three subjects with bilateral brain involvement had at the last visit a greater than 50% seizure reduction, reported ...

2.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/28454984/

Cannabidiol Treatment for Refractory Seizures in Sturge- ...

a greater than 50% seizure reduction, reported an improved quality of life, ed on cannabidiol 63-80 weeks … seizure management and provides initial data ...

Cannabidiol Treatment for Neurological, Cognitive, and ...

Epidiolex can improve quality of life and be beneficial for neurological, anxiety, and motor impairments in SWS independent of seizure control.

CBD May Improve Neurologic, Cognitive, QOL Outcomes ...

Epidiolex (cannabidiol [CBD]) may hold promise for seizure control in treatment-resistant Sturge-Weber syndrome (SWS), according to a new study ...

Epidiolex Trial for Presymptomatic Treatment of Sturge ...

This trial will evaluate whether Epidiolex in presymptomatic Sturge-Weber patients may delay the onset of seizures and improve neurological ...

6.

epidiolex.com

epidiolex.com/

EPIDIOLEX® (cannabidiol) for LGS, Dravet & TSC Seizures

EPIDIOLEX is a prescription medicine that is used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in ...

Epidiolex (Cannabidiol) Primer: Frequently Asked Questions ...

It is an FDA-approved, plant-derived, purified prescription cannabidiol, indicated for the treatment of seizures in patients 2 years and older.9

Cannabidiol Oral Solution | Anti-Seizure Medicine

EPIDIOLEX is a prescription medicine that is used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous ...

Frequently Asked Questions | EPIDIOLEX® (cannabidiol)

INDICATIONS: EPIDIOLEX (cannabidiol) oral solution is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) ...

EPIDIOLEX (cannabidiol) oral solution - accessdata.fda.gov

EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in ...